Orbimed Advisors LLC Verona Pharma PLC Transaction History

Orbimed Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$11.48 - $17.02 $6.16 Million - $9.13 Million	-536,266 Reduced 15.78%	2,861,801 $41.4 Million
Q1 2024 May 15, 2024	SELL	$15.3 - $20.24 $5.81 Million - $7.69 Million	-379,711 Reduced 10.05%	3,398,067 $54.7 Million
Q2 2023 Aug 14, 2023	SELL	$19.41 - $23.43 $9.37 Million - $11.3 Million	-482,913 Reduced 11.33%	3,777,778 $79.9 Million
Q1 2023 May 15, 2023	SELL	$18.06 - $25.27 $5.63 Million - $7.87 Million	-311,598 Reduced 6.81%	4,260,691 $85.6 Million
Q4 2022 Feb 14, 2023	SELL	$9.84 - $26.13 $11 Million - $29.3 Million	-1,122,552 Reduced 19.71%	4,572,289 $119 Million
Q3 2020 Nov 16, 2020	BUY	$4.45 - $10.2 $19.8 Million - $45.3 Million	4,444,445 Added 355.44%	5,694,841 $35.5 Million
Q4 2017 Feb 14, 2018	BUY	$10.8 - $15.75 $6.3 Million - $9.19 Million	583,730 Added 87.56%	1,250,396 $14.8 Million
Q3 2017 Nov 14, 2017	BUY	$11.96 - $16.95 $7.97 Million - $11.3 Million	666,666	666,666 $10.2 Million

167

68.7M

704K

685K

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $2.75B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.